Editorial: diabetes and its association with hepatocellular carcinoma in chronic hepatitis B by Konerman, M. & Loomba, R.
Invited Editorials
Editorial: diabetes and its association with
hepatocellular carcinoma in chronic
hepatitis B
M. Konerman* & R. Loomba†,‡,§
*Division of Gastroenterology and Hepatology, Department of
Medicine, University of Michigan, Ann Arbor, MI, USA.
†NAFLD Translational Research Unit, Division of Gastroenterology,
University of California at San Diego School of Medicine, La Jolla,
CA, USA.
‡Division of Gastroenterology, Department of Medicine, University of
California at San Diego School of Medicine, La Jolla, CA, USA.
§Division of Epidemiology, Department of Family and Preventive
Medicine, University of California at San Diego, La Jolla, CA, USA.
E-mail: roloomba@ucsd.edu
doi:10.1111/apt.13225
The impact of metabolic syndrome and its complica-
tions, namely hepatic steatosis and diabetes, have appro-
priately become focal points of investigation within
hepatology in the setting of the evolving obesity
epidemic. Although there is a large body of research that
has demonstrated an increased risk of hepatocellular car-
cinoma (HCC) in patients with diabetes, the specific
disease characteristics that modify this relationship
require further investigation.1 This is particularly the
case in patients with viral hepatitis, where studies have
produced conflicting data in terms of the independent
association of metabolic risk factors with HCC.1–4
In a recent issue, Fu et al. provide further data to sup-
port the observation of increased risk of HCC for dia-
betic patients with CHB.5 Using the Taiwanese National
Health Insurance Research Database, they included a
random sample of 2099 patients with CHB with new-
onset diabetes and 2080 age, gender and inception-point
matched nondiabetic patients. After adjusting for possi-
ble contributing factors, diabetes was an independent
predictor for HCC with a hazard ratio of 1.798.
This study has several strengths including a large sam-
ple-size, length of longitudinal follow-up and accounting
for multiple potential confounders for competing risk for
developing HCC. Several unaddressed questions remain,
however, particularly those stemming from the lack of his-
tology to address possible concomitant steatohepatitis. It is
well known that diabetes is an independent risk factor and
driver of steatohepatitis, and untreated steatohepatitis,
along with other metabolic dysregulations associated with
diabetes, have been shown to increase the risk of HCC in
the setting of hepatitis B infection.6, 7 Additionally, further
detail regarding duration of diabetes and control of diabe-
tes on the risk of HCC should also be evaluated.2, 3, 8, 9
Lastly, the impact of antidiabetic regimen should be
assessed as data has suggested decreased risk of HCC and
liver-related mortality in patients on metformin.8, 10 In
this study, only 39% of diabetics were on treatment and
the effect of diabetic treatment agents on HCC risk was
not assessed.
Overall, this study demonstrates the importance of
addressing modifiable metabolic risk factors in patients
with CHB. Lifestyle interventions to prevent obesity, dia-
betes and other features of the metabolic syndrome
should be emphasised in the care of patients with CHB.
Further studies are needed to clarify the attributable risk
of HCC in diabetics (such as duration and severity of
steatohepatitis), as well as optimal treatment of steato-
hepatitis, in order to minimise the risk of incident HCC
in CHB.
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We thank Konerman and Loomba for the excellent
editorial comments.1 Our large population-based study in
a hepatitis B virus endemic country with careful selection
of newly diagnosed diabetes strongly suggests that diabetes
superimposed on persistent hepatitis B infection promotes
the development of hepatocellular carcinoma (HCC).2
Previous studies disclosed the association between diabe-
tes and HCC in hepatitis B-infected patients.3–6 Our study
provides new evidence on temporal relationship by which
diabetes precedes HCC in patients with chronic hepatitis
B infection could infer a causal relationship, rather than
only association. Diabetes was an independent predictor
for HCC with an adjusted hazard ratio (AHR) of 1.798.
The risk was higher (AHR = 2.067, Table 1) among
patients with the duration of diabetes of more than
3 years, which further support the causal association.
The study design, to enrol newly diagnosed diabetes,
limited the potential to assess the control of diabetes
including diabetic treatment on the risk of HCC. As we
have shown, only 39% of diabetics were on therapy, thus
lacking the power to evaluate its effect on HCC risk. The
effect of diabetic control on the risk of HCC could only
be assessed in a different study design, which does not
exclude the pre-existing diabetes.
The effect of steatohepatitis on the risk of HCC in
patients with chronic hepatitis B plus new onset diabe-
tes is an interesting issue to be resolved. Although dia-
betes and its associated other metabolic dysregulations
have been shown to increase HCC risk in patients with
hepatitis B infection,6, 7 the contribution of steatohepa-
titis in these studies in unclear. In epidemiological and
database studies including huge number of patients and
samples, complete histological evaluation for consistent
diagnosis of steatohepatitis and its severity is a tremen-
dous challenge. Furthermore, as the therapy of steato-
hepatitis is still controversial, its treatment in patients
with chronic hepatitis B infection is even more chal-
lenging.
Table 1 | Risk factors for hepatocellular carcinoma:
Cox proportional hazard analysis in a population-based
cohort of chronic hepatitis B patients with new onset
diabetes
Adjusted
hazard ratio*
95% confidence
interval P value
Diabetes duration
>3 years 2.067 1.144–3.734 0.016
≤3 years 0.820 0.275–2.448 0.722
*Adjusted for age, gender, hyperlipidemia, chronic hepatitis B
treatment, statins therapy, cirrhosis, comorbidity index and
obesity.
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